- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05780320
A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Preoperative normal sinus rhythm
- Procedures:
- CABG
- CABG + concomitant valve or aortic replacement/repair
Exclusion Criteria:
- Emergent operation
Procedures:
- MAZE or PVI performed
- Isolated valve replacement or repair
- Isolated aortic procedures
- Heart transplant
- Lung transplant Pre-existing atrial arrhythmias Pre-operative amiodarone use Contraindications to amiodarone use
- PR interval > 240 ms
- 2nd or 3rd degree heart block
- QTc > 550ms
- 2nd or 3rd degree heart block
- Liver impairment (INR > 1.7, AST/ALT > 2x normal)
- Uncontrolled hypothyroidism/hyperthyroidism
- Interstitial lung disease
- Allergy to amiodarone
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pharmaco-Surgical Arm
|
Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy. The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first. The posterior pericardiotomy occurs during the cardiac procedure. |
Standard of Care Arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative atrial fibrillation
Time Frame: Prior to patient discharge or within 30 days after surgery.
|
At least 1 minute duration detected by continuous telemetry or 12-lead electrocardiogram.
|
Prior to patient discharge or within 30 days after surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initiation of systemic anticoagulation
Time Frame: Either in-hospital or within 30 days of procedure
|
New indication of systemic anticoagulation for stroke prophylaxis due to atrial fibrillation
|
Either in-hospital or within 30 days of procedure
|
Readmission
Time Frame: Within 30 days of procedure
|
Rates of hospital readmission will be estimated for patients in each of the study intervention groups.
Readmissions will be counted in this calculation if patients are admitted to the hospital.
Emergency room visits without admission and outpatient visits will not count toward this calculation of readmission rates.
|
Within 30 days of procedure
|
Symptomatic bradycardia
Time Frame: Either in-hospital or within 30 days of procedure
|
Symptomatic bradycardia (HR < 55 bpm) requiring intervention
|
Either in-hospital or within 30 days of procedure
|
Number of patients with Amiodarone-related pulmonary toxicity
Time Frame: Either in-hospital or within 30 days of procedure
|
Clinical diagnosis of amiodarone-related pulmonary toxicity that uses a combination of x-ray findings consistent with known amiodarone-related pulmonary toxicity and clinical findings including shortness of breath, non-productive cough, and other diagnoses have been excluded.
|
Either in-hospital or within 30 days of procedure
|
Operative mortality
Time Frame: Either in-hospital death or death within 30 days of discharge
|
Operative mortality as defined by either in-hospital death or death within 30 days of discharge.
|
Either in-hospital death or death within 30 days of discharge
|
Stroke
Time Frame: Either in-hospital or within 30 days of procedure
|
Characterized by deficits lasting > 24 hours and/or imaging findings of infarction
|
Either in-hospital or within 30 days of procedure
|
Transient ischemic attack
Time Frame: Either in-hospital or within 30 days of procedure
|
Characterized by examination findings lasting < 24 hours without associated imaging findings
|
Either in-hospital or within 30 days of procedure
|
Persistence of atrial fibrillation at discharge
Time Frame: At postoperative surgical visit (around 4-6 weeks)
|
Atrial fibrillation as diagnosed by final ECG
|
At postoperative surgical visit (around 4-6 weeks)
|
Postoperative hospital length of stay
Time Frame: Up to 90 days
|
The postoperative length of stay will be calculated starting from the end of the procedure to time of discharge
|
Up to 90 days
|
Postoperative pleural effusions requiring intervention
Time Frame: Either in-hospital or within 30 days of procedure
|
Postoperative pleural effusions requiring interventions including thoracostomy drainage or surgical drainage
|
Either in-hospital or within 30 days of procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Asishana A Osho, MD, MPH, Massachusetts General Hospital
Publications and helpful links
General Publications
- Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD003611. doi: 10.1002/14651858.CD003611.pub3.
- Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017 Oct 1;52(4):665-672. doi: 10.1093/ejcts/ezx039.
- Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis. Pacing Clin Electrophysiol. 2013 Aug;36(8):1017-23. doi: 10.1111/pace.12140. Epub 2013 Apr 29.
- Buckley MS, Nolan PE Jr, Slack MK, Tisdale JE, Hilleman DE, Copeland JG. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy. 2007 Mar;27(3):360-8. doi: 10.1592/phco.27.3.360.
- Colunga Biancatelli RM, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L. Adverse reactions of Amiodarone. J Geriatr Cardiol. 2019 Jul;16(7):552-566. doi: 10.11909/j.issn.1671-5411.2019.07.004.
- Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009 Jul;66(7):865-9. doi: 10.1001/archneurol.2009.96.
- Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009 Mar-Apr;16(2):43-8. doi: 10.1155/2009/282540.
- Gaudino M, Sanna T, Ballman KV, Robinson NB, Hameed I, Audisio K, Rahouma M, Di Franco A, Soletti GJ, Lau C, Rong LQ, Massetti M, Gillinov M, Ad N, Voisine P, DiMaio JM, Chikwe J, Fremes SE, Crea F, Puskas JD, Girardi L; PALACS Investigators. Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. Lancet. 2021 Dec 4;398(10316):2075-2083. doi: 10.1016/S0140-6736(21)02490-9. Epub 2021 Nov 14.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Enzyme Inhibitors
- Membrane Transport Modulators
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Sodium Channel Blockers
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Potassium Channel Blockers
- Amiodarone
Other Study ID Numbers
- 2004P001528
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation New Onset
-
University of OxfordRecruitingAtrial Fibrillation | Atrial Fibrillation New Onset | New Onset Atrial FibrillationUnited Kingdom
-
Seoul National University HospitalTerminatedAtrial Fibrillation New Onset | Atrial Fibrillation ParoxysmalKorea, Republic of
-
Danderyd HospitalKarolinska Institutet; Landstinget i VärmlandNot yet recruitingAtrial Fibrillation | Atrial Fibrillation New OnsetSweden
-
Population Health Research InstituteNot yet recruitingAtrial Fibrillation New Onset
-
Ain Shams UniversityRecruitingAtrial Fibrillation New OnsetEgypt
-
HagaZiekenhuisRecruitingAtrial Fibrillation New OnsetNetherlands
-
University of Maryland, BaltimoreRecruitingAtrial Fibrillation New OnsetUnited States
-
University of Massachusetts, WorcesterPfizerCompletedAtrial Fibrillation New OnsetUnited States
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial Fibrillation | Atrial Fibrillation New OnsetUnited States
-
University of Novi SadRecruitingAtrial Fibrillation New OnsetSerbia
Clinical Trials on Prophylactic amiodarone and posterior pericardiotomy
-
Weill Medical College of Cornell UniversityCatholic University of the Sacred HeartCompletedAtrial FibrillationUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownPersistent Occipital Posterior Presentation During Labor DeliveryFrance
-
The Catholic University of KoreaCompleted
-
Canadian Memorial Chiropractic CollegeCompleted
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedDuodenal Ulcer BleedingTurkey
-
Peking University Third HospitalSecond Affiliated Hospital, School of Medicine, Zhejiang University; Xuanwu... and other collaboratorsRecruitingIrreducible Atlantoaxial DislocationChina
-
ASST Fatebenefratelli SaccoNot yet recruitingPericardial Disease | Autoinflammatory Disease | Acute Pericarditis | Pericardial Effusion | Pericardial Fluid Exudate | Autoinflammatory Disorders
-
University of BernSonnenhof Hospital, BernTerminatedOsteoporosis | Vertebral FractureSwitzerland
-
Hovedstadens SygehusfaelesskabRigshospitalet, Denmark; Hvidovre University Hospital; Bispebjerg Hospital; Amager... and other collaboratorsCompletedDepressive Disorder | Bipolar DisorderDenmark